Eli Lilly and Company $LLY Stock: Laurel Wealth Advisors LLC Cuts Position

Laurel Wealth Advisors LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,556 shares of the company’s stock after selling 501 shares during the period. Eli Lilly and Company makes up about 1.5% of Laurel Wealth Advisors LLC’s investment portfolio, making the stock its 14th largest holding. Laurel Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $15,685,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Prism Planning Partners LLC purchased a new position in Eli Lilly and Company during the third quarter valued at $184,000. BLB&B Advisors LLC grew its stake in shares of Eli Lilly and Company by 8.6% in the third quarter. BLB&B Advisors LLC now owns 11,585 shares of the company’s stock worth $13,405,000 after acquiring an additional 915 shares during the last quarter. AMI Investment Management Inc. grew its stake in shares of Eli Lilly and Company by 55.2% in the third quarter. AMI Investment Management Inc. now owns 405 shares of the company’s stock worth $469,000 after acquiring an additional 144 shares during the last quarter. Sigma Investment Counselors Inc. grew its stake in shares of Eli Lilly and Company by 3.2% in the third quarter. Sigma Investment Counselors Inc. now owns 1,357 shares of the company’s stock worth $1,570,000 after acquiring an additional 42 shares during the last quarter. Finally, William Mack & Associates Inc. bought a new position in shares of Eli Lilly and Company during the third quarter valued at $117,000. Institutional investors own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Analyst Upgrades and Downgrades

LLY has been the subject of several recent analyst reports. Citigroup lifted their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research report on Friday. Truist Financial restated a “buy” rating and set a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday. TD Cowen reaffirmed a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Scotiabank upped their target price on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,398.43.

Eli Lilly and Company Stock Up 3.1%

LLY stock opened at $1,415.64 on Friday. The stock has a market capitalization of $1.33 trillion, a P/E ratio of 45.95, a P/E/G ratio of 1.73 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $834.19 and a 1-year high of $1,449.68. The business has a fifty day moving average price of $1,197.72 and a 200-day moving average price of $1,092.57.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 93.68% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same period last year, the firm posted $7.02 earnings per share. Eli Lilly and Company’s revenue was up 38.6% compared to the same quarter last year. Equities analysts forecast that Eli Lilly and Company will post 35.50 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.